Visteon (NASDAQ:VC – Get Free Report) and Aspire Biopharma (NASDAQ:ASBP – Get Free Report) are both consumer discretionary companies, but which is the better stock? We will contrast the two businesses based on the strength of their valuation, profitability, dividends, analyst recommendations, institutional ownership, earnings and risk.
Profitability
This table compares Visteon and Aspire Biopharma’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Visteon | 5.58% | 14.61% | 7.07% |
| Aspire Biopharma | -11,362.21% | N/A | -177.59% |
Insider & Institutional Ownership
99.7% of Visteon shares are held by institutional investors. Comparatively, 19.2% of Aspire Biopharma shares are held by institutional investors. 2.0% of Visteon shares are held by company insiders. Comparatively, 5.8% of Aspire Biopharma shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.
Risk and Volatility
Analyst Recommendations
This is a breakdown of recent ratings and target prices for Visteon and Aspire Biopharma, as provided by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Visteon | 0 | 5 | 8 | 0 | 2.62 |
| Aspire Biopharma | 1 | 0 | 0 | 0 | 1.00 |
Visteon currently has a consensus target price of $127.00, indicating a potential upside of 48.66%. Given Visteon’s stronger consensus rating and higher probable upside, analysts clearly believe Visteon is more favorable than Aspire Biopharma.
Valuation & Earnings
This table compares Visteon and Aspire Biopharma”s top-line revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Visteon | $3.77 billion | 0.61 | $201.00 million | $7.65 | 11.17 |
| Aspire Biopharma | $10,000.00 | 1,162.00 | -$24.48 million | ($69.62) | -0.12 |
Visteon has higher revenue and earnings than Aspire Biopharma. Aspire Biopharma is trading at a lower price-to-earnings ratio than Visteon, indicating that it is currently the more affordable of the two stocks.
Summary
Visteon beats Aspire Biopharma on 12 of the 14 factors compared between the two stocks.
About Visteon
Visteon Corporation, an automotive technology company, designs, manufactures, and sells automotive electronics and connected car solutions for vehicle manufacturers worldwide. The company provides instrument clusters, including analog gauge clusters for 2-D and 3-D display-based devices; information displays that integrate a range of user interface technologies and graphics management capabilities, such as active privacy, TrueColor enhancement, local dimming, cameras, optics, haptic feedback, and light effects; and infotainment and connected car solutions, including scalable Android infotainment for seamless connectivity, as well as onboard artificial intelligence-based voice assistants with natural language understanding. It offers wired and wireless battery management systems; power electronics units; and telematics control units to enable secure connected car services, software updates, and data. In addition, the company provides SmartCore, an automotive-grade, integrated domain controller; SmartCore Runtime, a middleware enabling communication between domains and apps to be shown on any display; SmartCore Studio, a PC-based configuration tool to generate hypervisor configurations; and body domain modules, which integrate various functions, such as central gateway, body controls, comfort, and vehicle access solutions, into one device. Visteon Corporation was incorporated in 2000 and is headquartered in Van Buren, Michigan.
About Aspire Biopharma
Aspire Biopharma Holdings, Inc., early-stage biopharmaceutical company, engages in developing and marketing of disruptive technology for delivery mechanisms for do no harm drugs in the United States. The company provides Sublingual Aspirin Product, which addresses cardiology emergencies and pain management. It develops formulation for a sublingually administered melatonin sleep-aid product; vitamins D, E, and K; testosterone; and semaglutide, as well as formulations for anti-nausea products, anti-psychotic products, ED drugs, seizure medication, and several other classes of drugs. The company was founded in 2021 and is based in Humacao, Puerto Rico.
Receive News & Ratings for Visteon Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Visteon and related companies with MarketBeat.com's FREE daily email newsletter.
